文献速递前列腺癌

PRIMARY试验方案:PSMA-PET/CT联合mpMRI诊断前列腺癌的前瞻性多中心横断面研究

Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
PubMed 文献 · BJU Int · 2020-02-12

PRIMARY试验是一项前瞻性多中心横断面诊断研究,计划招募最多600例疑似前列腺癌拟行初次活检的男性,评估镓-68 PSMA-PET/CT联合mpMRI检测临床显著前列腺癌(csPCa)的附加诊断价值。研究将比较两种影像与靶向穿刺活检的敏感性、特异性、阳性预测值和阴性预测值,并确定mpMRI阳性(PI-RADS≥3)但PSMA-PET/CT阴性的男性中可安全避免活检的比例。

要点

  • PSMA-PET/CT联合mpMRI可能提高csPCa检出并减少不必要活检。
  • 研究采用经会阴模板+靶向穿刺作为参考标准,影像判读互盲。
  • 将评估PSMA-PET/CT纳入诊断路径的卫生经济学获益与风险。

核心结论

  • PRIMARY试验将提供前瞻性数据,确定PSMA-PET/CT在mpMRI基础上对csPCa的诊断能力,并明确哪些患者可避免活检。

研究设计与样本

  • 多中心、前瞻性、横断面诊断试验,符合诊断试验评价的1级证据标准。
  • 计划招募最多600例疑似前列腺癌拟行初次活检的男性。
  • 所有受试者接受PSMA-PET/CT(指数试验)、mpMRI(标准试验)和经会阴模板+靶向(PSMA-PET/CT和/或mpMRI)穿刺活检(参考试验)。
  • mpMRI与PSMA-PET/CT的实施与报告互盲。

关键数值与推荐

  • 主要目标:确定PSMA-PET/CT联合mpMRI检测csPCa的附加价值,以及mpMRI阳性(PI-RADS≥3)但PSMA-PET/CT阴性者可避免活检的比例。
  • 次要目标:确定仅由PSMA-PET/CT或仅由系统穿刺活检检出csPCa的比例。
  • 次要目标:比较模板穿刺指数病灶与mpMRI或PSMA-PET/CT靶向病灶。
  • 次要目标:评估将PSMA-PET/CT纳入诊断算法的卫生经济学获益或损害。
  • 次要目标:开发结合临床、影像和生物标志物数据预测csPCa可能性的列线图。

临床怎么用

  • 若验证有效,PSMA-PET/CT联合mpMRI可优化疑似前列腺癌患者的活检决策,减少不必要穿刺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary objectives: To determine the additive value of gallium-68 prostate-specific membrane antigen (PSMA) positron emission topography (PET)/computed tomography (CT) when combined with multiparametric magnetic resonance imaging (mpMRI) detecting clinically significant prostate cancer (csPCa) in men undergoing initial biopsy for suspicion of PCa, and to determine the proportion of men who could have avoided prostate biopsy with positive mpMRI (PI-RADS ≥3) but negative PSMA-PET/CT. Secondary objectives: To determine the proportion of men who had csPCa detected only by PSMA-PET/CT or only by systematic prostate biopsy; to compare index lesions by template biopsies vs targeted lesions identified on mpMRI or PSMA-PET/CT; to assess whether there may be health economic benefit or harm if PSMA-PET/CT is incorporated into the diagnostic algorithm; and to develop a nomogram which combines clinical, imaging and biomarker data to predict the likelihood of csPCa. PATIENTS AND METHODS: The PRIMARY trial is a multicentre, prospective, cross-sectional study that meets the criteria for level 1 evidence in diagnostic test evaluation. PRIMARY will investigate if a limited (pelvic-only) PSMA-PET/CT in combination with routine mpMRI can reliably discriminate men with csPCa from those without csPCa. We conducted a power calculation based on pilot data and will recruit up to 600 men who will undergo PSMA-PET/CT (the index test), mpMRI (standard test) and transperineal template + targeted (PSMA-PET/CT and/or mpMRI) biopsies (reference test). The conduct and reporting of the mpMRI and PSMA-PET/CT will be blinded to each other. RESULTS: The PRIMARY trial will measure and compare sensitivity, specificity, positive predictive value and negative predictive value of both mpMRI and PSMA-PET/CT vs targeted prostrate biopsy. The results will be used to determine the proportion of men who could safely avoid biopsy without compromising detection of csPCa. Furthermore, we will assess whether there is a health economic benefit in incorporating PSMA-PET/CT into the diagnostic algorithm. CONCLUSIONS: This trial will provide robust prospective data to determine the diagnostic ability of PSMA-PET/CT used in addition to mpMRI. It will establish if certain patients can avoid biopsy in the investigation of PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Amin A, Blazevski A, Thompson J, et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int. 2020. PMID: 31957122. doi:10.1111/bju.14999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。